Improving outcomes in children with sickle cell disease: Treatment considerations and strategies

Pediatric Drugs

Volumn 16, Issue 4, 2014, Pages 255-266

  Amid, Ali ^a,b   Odame, Isaac ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; HYDROXYUREA;

ACUTE CHEST SYNDROME; ANALGESIA; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CEREBROVASCULAR ACCIDENT; DRUG TOLERABILITY; EARLY DIAGNOSIS; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED PRACTICE; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; LOWEST INCOME GROUP; MYELOPROLIFERATIVE DISORDER; NEWBORN SCREENING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SECONDARY HEALTH CARE; SICKLE CELL ANEMIA; ANEMIA, SICKLE CELL; ANTIBIOTIC PROPHYLAXIS; CHILD; COMPLICATION; COST;

ACUTE CHEST SYNDROME; ANEMIA, SICKLE CELL; ANTIBIOTIC PROPHYLAXIS; CHILD; COSTS AND COST ANALYSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYUREA; PAIN MANAGEMENT;

EID: 84905504989     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-014-0074-4     Document Type: Review

References (133)

1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-44.
2. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018-31.
3. Panepinto JA, O'Mahar KM, DeBaun MR, et al. Health-related QOL in children with sickle cell disease: child and parent perception. Br J Haematol. 2005;130:437-44. (Pubitemid 43899594)
4. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381 (9861):142-51.
5. Allison AC. Protection afforded by sickle-cell trait against subtertian malareal infection. Br Med J. 1954;1(4857):290-4.
6. May J, Evans JA, Timmann C, et al. Hemoglobin variants and disease manifestations in severe falciparum malaria. JAMA. 2007;297:2220-6. (Pubitemid 47010879)
7. Williams TN, Mwangi TW, Wambua S, et al. Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. J Infect Dis. 2005;192:178-86. (Pubitemid 40863872)
8. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115:3447-52.
9. Lee A, Thomas P, Cupidore L, et al. Improved survival in homozygous sickle cell disease: lessons from a cohort study. BMJ. 1995;7020:1600-2. (Pubitemid 26002704)
10. Prabhakar H, Haywood C Jr, Molokie R. Sickle cell disease in the United States: looking back and forward at 100 years of progress in management and survival. Am J Hematol. 2010;85(5):346-53.
11. World Health Organization. Sickle-cell anaemia: Report by the Secretariat. World Health Organization, Fifty-Ninth World Health Assembly A59/9, Provisional agenda item 11.4; 2006.
12. Aygun B, Odame I. A global perspective on sickle cell disease. Pediatr Blood Cancer. 2012;59:386-90.
13. Garenne M, Gakusi E. Health transitions in sub-Saharan Africa: overview of mortality trends in children under 5 years old (1950-2000). Bull World Health Organ. 2006;84:470-8. (Pubitemid 43845447)
14. Sickle cell anaemia. Agenda item 11.4. In: 59th World Health Assembly; 2006. EB118.R1. http://www.who.int/gb/ebwha/pdf-files/EBSS-EB118-2006-REC1/ english/Res/reseb118-2006-rec1-en.pdf.
15. Odame I. Developing a global agenda for sickle cell disease: report of an international symposium and workshop in Cotonou, Republic of Benin. Am J Prev Med. 2010;38:S571-5.
16. Odame I, Kulkarni R, Ohene-Frempong K. Concerted global effort to combat sickle cell disease: the first global congress on sickle cell disease in Accra, Ghana. Am J Prev Med. 2011;41:S417-21.
17. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115:5300-11.
18. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012;120:3647-56.
19. Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature. 1957;180(4581):326-8.
20. Hahn E, Gillepsie E. Sickle cell anemia: report of a case greatly improved by splenectomy. Arch Intern Med. 1927;39:233-54.
21. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004;364(9442):1343-60. (Pubitemid 39335827)
22. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21:37-47. (Pubitemid 46110926)
23. Frei-Jones MJ, Field JJ, DeBaun MR. Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease. Pediatr Blood Cancer. 2009;52:481-5.
24. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79:17-25. (Pubitemid 40604787)
25. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: rates and risk factors. N Engl J Med. 1991;325:11-6.
26. Prasad R, Hasan S, Castro O, et al. Long-term outcomes in patients with sickle cell disease and frequent vaso-occlusive crises. Am J Med Sci. 2003;325:107-9. (Pubitemid 36348614)
27. Baum K, Dunn DT, Maude GH, Serjeant GR. The painful crisis of homozygous sickle cell disease: a study of risk factors. Arch Intern Med. 1987;147:1231-4. (Pubitemid 17102149)
28. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106:337-8. (Pubitemid 30655633)
29. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106:411-20. (Pubitemid 30655641)
30. Co LL, Schmitz H, Havdala H, et al. Acupuncture: an evaluation in the painful crises of sickle cell anaemia. Pain. 1979;7:181-5. (Pubitemid 10198512)
31. Anie KA, Green J. Psychological therapies for sickle cell disease and pain. Cochrane Database Syst Rev. 2012;2:CD001916.
32. Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood. 2000;95:1130-6.
33. Rees DC, Olujohungbe AD, Parker NE, et al. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol. 2003;120:744-52. (Pubitemid 36315093)
34. Keeley K, Buchanan GR. Acute infarction of long bones in children with sickle cell anemia. J Pediatr. 1982;101:170-5. (Pubitemid 12098761)
35. Rees DC, Olujohungbe AD, Parker NE, et al. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol. 2003;120(5):744-52. (Pubitemid 36315093)
36. van Beers EJ, van Tuijn CF, Nieuwkerk PT, et al. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. Am J Hematol. 2007;82:955-60. (Pubitemid 350004385)
37. Gerber N, Apseloff G. Death from a morphine infusion during a sickle cell crisis. J Pediatr. 1993;123:322-5. (Pubitemid 23221122)
38. Buchanan ID, Woodward M, Reed GW. Opioid selection during sickle cell pain crisis and its impact on the development of acute chest syndrome. Pediatr Blood Cancer. 2005;45:716-24. (Pubitemid 41279365)
39. Lewing K, Britton K, DeBaun M, Woods G. The impact of parenteral narcotic choice in the development of acute chest syndrome in sickle cell disease. J Pediatr Hematol Oncol. 2011;33:255-60.
40. Birken CS, Khambalia A, Dupuis A, et al. Morphine is associated with acute chest syndrome in children hospitalized with sickle cell disease. Hosp Pediatr. 2013;3:149-55.
41. Bellet PS, Kalinyak KA, Shukla R, et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med. 1995;333:699-703.
42. Liu JE, Gzesh DJ, Ballas SK. The spectrum of epilepsy in sickle cell anemia. J Neurol Sci. 1994;123:6-10. (Pubitemid 24167420)
43. O'Brien SH, Fan L, Kelleher KJ. Inpatient use of laxatives during opioid administration in children with sickle cell disease. Pediatr Blood Cancer. 2010;54(4):559-62.
44. Okpala I, Tawil A. Management of pain in sickle-cell disease. J R Soc Med. 2002;95(9):456-8.
45. Zempsky WT. Treatment of sickle cell pain: fostering trust and justice. JAMA. 2009;302(22):2479-80.
46. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med. 1994;331(25):1675-9. (Pubitemid 24373619)
47. Chang J, Patton JT, Sarkar A. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood. 2010;116(10):1779-86.
48. McCavit TL, Krishnamurti L, Hsu LL, et al. An analysis of the pediatric sub-group from the phase 2 study of GMI 1070 - a novel agent for the vaso-occlusive crisis of sickle cell anemia. Blood. 2013;122:abstract 2206.
49. Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 2013;122(24):3892-8.
50. Brown AK, Sleeper LA, Miller ST, et al. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Arch Pediatr Adolesc Med. 1994;148:796-804. (Pubitemid 24243769)
51. Lane PA, O'Connell JL, Kear JL, et al. Functional asplenia in hemoglobin SC disease. Blood. 1995;85:2238-44.
52. Johnston RB Jr, Newman SL, Struth AG. An abnormality of the alternate pathway of complement activation in sickle-cell disease. N Engl J Med. 1973;288:803-8.
53. Robinson MG, Watson RJ. Pneumococcal meningitis in sickle-cell anemia. N Engl J Med. 1966;274:1006-8.
54. Pearson HA. Sickle cell anemia and serious infections due to encapsulated bacteria. J Infect Dis. 1977;136(suppl):S25-30. (Pubitemid 8171397)
55. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med. 1986;314(25):1593-9. (Pubitemid 16118215)
56. Ammann AJ, Addiego J, Wara DW, et al. Polyvalent pneumococcal- polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engl J Med. 1977;297:897-900. (Pubitemid 8211943)
57. Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44:1428-33. (Pubitemid 46801584)
58. Falletta JM, Woods GM, Verter JI. Discontinuing penicillin prophylaxis in children with sickle cell anemia. J Pediatr. 1995;127:685-90.
59. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood. 1995;86(2):776-83.
60. Rogers ZR, Buchanan GR. Bacteremia in children with sickle hemoglobin C disease and sickle beta? thalassemia: is prophylactic penicillin necessary? J Pediatr. 1995;127:348-53.
61. Teach SJ, Lillis KA, Grossi M. Compliance with penicillin prophylaxis in patients with sickle cell disease. Arch Pediatr Adolesc Med. 1998;152:274-8. (Pubitemid 28124516)
62. Buchanan GR, Siegel JD, Smith SJ, DePasse BM. Oral penicillin prophylaxis in children with impaired splenic function: a study of compliance. Pediatrics. 1982;70:926-30. (Pubitemid 13247245)
63. Berkovitch M, Papadouris D, Shaw D, et al. Trying to improve compliance with prophylactic penicillin therapy in children with sickle cell disease. Br J Clin Pharmacol. 1998;45:605-7. (Pubitemid 28270918)
64. Rahimy MC, Gangbo A, Ahouignan G, et al. Effect of a comprehensive clinical care program on disease course in severely ill children with sickle cell anemia in a sub-Saharan African setting. Blood. 2003;102:834-8. (Pubitemid 36917772)
65. Wilimas JA, Flynn PM, Harris S, et al. A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease. N Engl J Med. 1993;329:472-6. (Pubitemid 23222333)
66. Rogers ZR, Morrison RA, Vedro DA, Buchanan GR. Outpatient management of febrile illness in infants and young children with sickle cell anemia. J Pediatr. 1990;117:736-9. (Pubitemid 20382605)
67. Bakshi SS, Grover R, Cabezon E, Wethers DL. Febrile episodes in children with sickle cell disease treated on an ambulatory basis. J Assoc Acad Minor Phys. 1991;2:80-3.
68. Oniyangi O, Omari AA. Malaria chemoprophylaxis in sickle cell disease. Cochrane Database Syst Rev. 2003;3:CD003489.
69. Leikin SL, Gallagher D, Kinney TR, et al. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics. 1989;84:500-8. (Pubitemid 19216350)
70. Vichinsky E, Hurst D, Earles A, Kleman A, Lubin P. Newborn screening for sickle cell disease: effect on mortality. Pediatrics. 1988;81:749-55.
71. Ebrahim SH, Khoja TA, Elachola H, et al. Children who come and go: the state of sickle cell disease in resource-poor countries. Am J Prev Med. 2010;38:S568-70.
72. Rahimy MC. Early detection and medical management of sickle cell anemia: five years of experience in Cotonou. Arch Pediatr. 1999;6:343-4.
73. Kafando E, Sawadogo M, Cotton F, et al. Neonatal screening for sickle cell disorders in Ouagadougou, Burkina Faso: a pilot study. J Med Screen. 2005;12:112-4. (Pubitemid 41337141)
74. Ohene-Frempong K, Oduro J, Tetteh H, et al. Screening newborns for sickle cell disease in Ghana. Pediatrics. 2008;121:S120-1.
75. Mutesa L, Boemer F, Ngendahayo L, et al. Neonatal screening for sickle cell disease in Central Africa: a study of 1825 new-borns with a new enzyme-linked immunosorbent assay test. J Med Screen. 2007;14:113-6. (Pubitemid 47511119)
76. Bain BJ. Neonatal/newborn haemoglobinopathy screening in Europe and Africa. J Clin Pathol. 2009;62:53-6.
77. Jani IV, Peter TF. How point-of-care testing could drive innovation in global health. N Engl J Med. 2013;368:2319-24.
78. Gray J, Anionwu EN, Davies SC, Brozovic M. Patterns of mortality in sickle cell disease in the United Kingdom. J Clin Pathol. 1991;44:459-63.
79. Thomas AN, Pattison C, Serjeant GR. Causes of death in sickle-cell disease in Jamaica. Br Med J. 1982;285(6342):633-5. (Pubitemid 12042696)
80. Powars D, Weidman JA, Odom-Maryon T, et al. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore). 1988;67:66-76. (Pubitemid 18064307)
81. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342:1855-65. (Pubitemid 30419049)
82. Stuart MJ, Setty BN. Acute chest syndrome of sickle cell disease: new light on an old problem. Curr Opin Hematol. 2001;8:111-22. (Pubitemid 32207560)
83. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood. 1994;84: 643-9. (Pubitemid 24215969)
84. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood. 2006;108(9):2923-7.
85. Davies SC, Luce PJ, Win AA, et al. Acute chest syndrome in sickle-cell disease. Lancet. 1984;1(8367):36-8. (Pubitemid 14213491)
86. Vichinsky EP, Styles LA, Colangelo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood. 1997;89:1787-92. (Pubitemid 27097475)
87. Dean D, Neumayr L, Kelly DM, et al. Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease. J Pediatr Hematol Oncol. 2003;25:46-55. (Pubitemid 36070964)
88. Paul RN, Castro OL, Aggarwal A, Oneal PA. Acute chest syndrome: sickle cell disease. Eur J Haematol. 2011;87:191-207.
89. Neumayr L, Lennette E, Kelly D, et al. Mycoplasma disease and acute chest syndrome in sickle cell disease. Pediatrics. 2003;112:87-95. (Pubitemid 36792934)
90. Miller ST. How I treat acute chest syndrome in children with sickle cell disease. Blood. 2011;117:5297-305.
91. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2001;139:785-9. (Pubitemid 34014456)
92. Verduzco LA, Nathan DG. Sickle cell disease and stroke. Blood. 2009;114:5117-25.
93. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288-94. (Pubitemid 28018756)
94. Vichinsky EP, Neumayr LD, Gold JI, et al. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA. 2010;303:1823-31.
95. Armstrong FD, Thompson RJ Jr, Wang W, et al. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease: Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Pediatrics. 1996;97:864-70.
96. Miller ST, Macklin EA, Pegelow CH, et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr. 2001;139:385-90. (Pubitemid 32889515)
97. O'Driscoll S, Height SE, Dick MC, Rees DC. Serum lactate dehydrogenase activity as a biomarker in children with sickle cell disease. Br J Haematol. 2008;140:206-9. (Pubitemid 350265040)
98. Bernaudin F, Verlhac S, Chevret S, et al. G6PD deficiency, absence of alpha-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia. Blood. 2008;112:4314-7.
99. Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am J Med. 1978;65:461-71. (Pubitemid 8397664)
100. Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med. 1992;326:605-10.
101. Adams RJ, McKie VC, Carl EM, et al. Long term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol. 1997;42:699-704. (Pubitemid 27481541)
102. Fullerton HJ, Adams RJ, Zhao S, Johnston SC. Declining stroke rates in Californian children with sickle cell disease. Blood. 2004;104:336-9. (Pubitemid 38900012)
103. Adams RJ, Brambilla D, Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769-78. (Pubitemid 43016816)
104. Zimmerman SA, Schultz WH, Burgett S, et al. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood. 2007;110:1043-7. (Pubitemid 47267446)
105. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood. 1999;94:3022-6. (Pubitemid 29512706)
106. Ware RE, Helms RW, SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood. 2012;119:3925-32.
107. de Montalembert M. To SWiTCH or not to SWiTCH? Blood. 2012;119:3870-1.
108. Ali SB, Moosang M, King L, et al. Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke. Am J Hematol. 2011;86:846-50.
109. Emond AM, Collis R, Darvill D, et al. Acute splenic sequestration in homozygous sickle cell disease: natural history and management. J Pediatr. 1985;107:201-6. (Pubitemid 15241908)
110. Kinney TR, Ware RE, Schultz WH, Filston HC. Long-term management of splenic sequestration in children with sickle cell disease. J Pediatr. 1990;117:194-9. (Pubitemid 20238529)
111. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663-72.
112. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood. 1996;88:1960-4. (Pubitemid 26307897)
113. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332:1317-22.
114. Scott JP, Hillery CA, Brown ER, et al. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr. 1996;128:820-8. (Pubitemid 26181380)
115. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94:1550-4. (Pubitemid 29411304)
116. Khayat AS, Antunes LM, Guimarães AC, et al. Cytotoxic and genotoxic monitoring of sickle cell anemia patients treated with hydroxyurea. Clin Exp Med. 2006;6:33-7.
117. de Montalembert M, Begue P, Bernaudin F, et al. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. Arch Dis Child. 1999;81:437-9. (Pubitemid 29501380)
118. Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica. 2008;93:988-93. (Pubitemid 351957015)
119. Ballas SK, McCarthy WF, Guo N, et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc. 2009;101:1046-51.
120. Wang WC, Helms RW, Lynn HS, et al. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS study. J Pediatr. 2002;140:225-9. (Pubitemid 34183663)
121. Kutlar A, Ataga K, Reid M, et al. A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2012;87:1017-21.
122. Gutsaeva DR, Parkerson JB, Yerigenahally SD, et al. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood. 2011;117:727-35.
123. Ohene-Frempong K. Indications for red cell transfusion in sickle cell disease. Semin Hematol. 2001;38:5-13. (Pubitemid 32110267)
124. Osaro E, Charles AT. The challenges of meeting the blood transfusion requirements in Sub-Saharan Africa: the need for the development of alternatives to allogenic blood. J Blood Med. 2011;2:7-21.
125. Tagny CT, Mbanya D, Tapko JB, Lefrère JJ. Blood safety in Sub-Saharan Africa: a multi-factorial problem. Transfusion. 2008;48:1256-61. (Pubitemid 351793507)
126. Lagunju IA, Brown BJ, Sodeinde OO. Chronic blood transfusion for primary and secondary stroke prevention in Nigerian children with sickle cell disease: a 5-year appraisal. Pediatr Blood Cancer. 2013. doi:10.1002/pbc.24698.
127. Cox JV, Steane E, Cunningham G, Frenkel EP. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med. 1988;148:2485-9.
128. Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136:501-8. (Pubitemid 46046309)
129. Hsieh MM, Fitzhugh CD, Tisdale JF. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood. 2011;118:1197-207.
130. Borgmann-Staudt A, Rendtorff R, Reinmuth S, et al. Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence. Bone Marrow Transplant. 2012;47(2):271-6.
131. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007;318(5858):1920-3.
132. Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 2001;294(5550):2368-71. (Pubitemid 33140563)
133. McPherson M, Thaniel L, Minniti CP. Transition of patients with sickle cell disease from pediatric to adult care: assessing patient readiness. Pediatr Blood Cancer. 2009;52:838-41.